GlassScriptPhysician profile
Mark Fernandez
NPI 1881860013
$2,440.10
in general payments reported to CMS, 2019-2025
24 companies · $714 in 2025
The $714 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2020: $91.49 · 2021: $184 · 2022: $490 · 2023: $297 · 2024: $526 · 2025: $714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,536.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,536.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $400.57 | 2022-2025 | |
| Alcon Vision LLC | $348.36 | 2019-2025 | Argos, Hydrus Microstent, Clareon |
| Horizon Therapeutics Plc | $240.03 | 2022-2023 | Tepezza |
| Sun Pharmaceutical Industries INC. | $160.31 | 2022-2025 | Cequa |
| Dompe US, INC. | $129.83 | 2020-2025 | Oxervate |
| Allergan, INC. | $119.51 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $116.40 | 2024-2025 | Xdemvy |
| Mallinckrodt Hospital Products INC. | $96.06 | 2024 | Acthar |
| Oyster Point Pharma, INC. | $86.75 | 2022-2023 | Tyrvaya |
| Alexion Pharmaceuticals, INC. | $86.30 | 2022-2025 | Ultomiris |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $83.53 | 2019-2021 | |
| Harrow Eye, LLC | $76.08 | 2024-2025 | Vevye |
| Kala Pharmaceuticals, INC. | $69.68 | 2019-2021 | |
| Amgen INC. | $67.23 | 2024 | Tepezza |
| Thea Pharma INC. | $66.08 | 2022-2025 | Iyuzeh |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $55.15 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $38.41 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $38.14 | 2022-2023 | Prolensa, Vyzulta |
| Biotissue Holdings INC. | $32.37 | 2020-2022 | |
| Ucb, INC. | $30.31 | 2025 | Rystiggo |
| Glaukos Corporation | $29.99 | 2024 | Idose |
| Rxsight INC | $27.77 | 2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| New World Medical,INC. | $21.62 | 2024 | Ahmed Glaucoma Valve, Clearpath, Kahook Dual Blade |
| Omeros Corporation | $19.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Fernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.